Halozyme Therapeutics, Inc. (HALO)
69.29
+2.65
(+3.98%)
USD |
NASDAQ |
Apr 17, 16:00
69.34
+0.05
(+0.07%)
Pre-Market: 20:00
Halozyme Therapeutics Cash from Investing (Quarterly) : -741.79M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -- |
| Eli Lilly & Co. | -2.802B |
| Vertex Pharmaceuticals, Inc. | -288.10M |
| Baxter International, Inc. | -198.00M |
| Glaukos Corp. | -15.89M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 219.03M |
| Cash from Financing (Quarterly) | 239.52M |
| Free Cash Flow | 644.59M |
| Free Cash Flow Per Share (Quarterly) | 1.849 |
| Free Cash Flow to Equity (Quarterly) | -448.84M |
| Free Cash Flow to Firm (Quarterly) | 224.50M |
| Free Cash Flow Yield | 7.58% |